Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. more
Time Frame | TYRA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.22% | -3.39% | 0.2% |
1-Month Return | -1.62% | -1.92% | 2.72% |
3-Month Return | -31.93% | -10.54% | 7.31% |
6-Month Return | -14.25% | -4.47% | 10.44% |
1-Year Return | 17.17% | 4.06% | 27.53% |
3-Year Return | 21.66% | 0.94% | 30.88% |
5-Year Return | -41.46% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 8.00K | 47.00K | 140.00K | 296.00K | 353.00K | [{"date":"2019-12-31","value":2.27,"profit":true},{"date":"2020-12-31","value":13.31,"profit":true},{"date":"2021-12-31","value":39.66,"profit":true},{"date":"2022-12-31","value":83.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (8.00K) | (47.00K) | (140.00K) | (296.00K) | (353.00K) | [{"date":"2019-12-31","value":-800000,"profit":false},{"date":"2020-12-31","value":-4700000,"profit":false},{"date":"2021-12-31","value":-14000000,"profit":false},{"date":"2022-12-31","value":-29600000,"profit":false},{"date":"2023-12-31","value":-35300000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 3.12M | 9.30M | 26.29M | 58.93M | 79.94M | [{"date":"2019-12-31","value":3.91,"profit":true},{"date":"2020-12-31","value":11.63,"profit":true},{"date":"2021-12-31","value":32.88,"profit":true},{"date":"2022-12-31","value":73.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (3.12M) | (9.30M) | (26.29M) | (58.93M) | (79.94M) | [{"date":"2019-12-31","value":-312200000,"profit":false},{"date":"2020-12-31","value":-929700000,"profit":false},{"date":"2021-12-31","value":-2628800000,"profit":false},{"date":"2022-12-31","value":-5892700000,"profit":false},{"date":"2023-12-31","value":-7994500000,"profit":false}] |
Total Non-Operating Income/Expense | (944.00K) | (40.00K) | 7.00K | 7.25M | 21.66M | [{"date":"2019-12-31","value":-4.36,"profit":false},{"date":"2020-12-31","value":-0.18,"profit":false},{"date":"2021-12-31","value":0.03,"profit":true},{"date":"2022-12-31","value":33.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (4.07M) | (9.34M) | (26.29M) | (55.33M) | (69.13M) | [{"date":"2019-12-31","value":-406500000,"profit":false},{"date":"2020-12-31","value":-933600000,"profit":false},{"date":"2021-12-31","value":-2629400000,"profit":false},{"date":"2022-12-31","value":-5532500000,"profit":false},{"date":"2023-12-31","value":-6913400000,"profit":false}] |
Income Taxes | (7.00K) | (22.00K) | (153.00K) | (3.60M) | - | [{"date":"2019-12-31","value":-700000,"profit":false},{"date":"2020-12-31","value":-2200000,"profit":false},{"date":"2021-12-31","value":-15300000,"profit":false},{"date":"2022-12-31","value":-360200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (4.06M) | (9.31M) | (26.14M) | (51.72M) | - | [{"date":"2019-12-31","value":-405800000,"profit":false},{"date":"2020-12-31","value":-931400000,"profit":false},{"date":"2021-12-31","value":-2614100000,"profit":false},{"date":"2022-12-31","value":-5172300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (4.07M) | (9.34M) | (26.29M) | (55.33M) | (69.13M) | [{"date":"2019-12-31","value":-406500000,"profit":false},{"date":"2020-12-31","value":-933600000,"profit":false},{"date":"2021-12-31","value":-2629400000,"profit":false},{"date":"2022-12-31","value":-5532500000,"profit":false},{"date":"2023-12-31","value":-6913400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.06M) | (9.31M) | (26.14M) | (51.72M) | (69.13M) | [{"date":"2019-12-31","value":-405800000,"profit":false},{"date":"2020-12-31","value":-931400000,"profit":false},{"date":"2021-12-31","value":-2614100000,"profit":false},{"date":"2022-12-31","value":-5172300000,"profit":false},{"date":"2023-12-31","value":-6913400000,"profit":false}] |
EPS (Diluted) | (1.07) | (6.97) | (1.24) | (1.33) | (1.61) | [{"date":"2019-12-31","value":-106.7,"profit":false},{"date":"2020-12-31","value":-697.2,"profit":false},{"date":"2021-12-31","value":-124,"profit":false},{"date":"2022-12-31","value":-133,"profit":false},{"date":"2023-12-31","value":-161,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TYRA | |
---|---|
Cash Ratio | 29.11 |
Current Ratio | 29.55 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TYRA | |
---|---|
ROA (LTM) | -20.21% |
ROE (LTM) | -28.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TYRA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TYRA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.13 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Tyra Biosciences Inc (TYRA) share price today is $14.465
Yes, Indians can buy shares of Tyra Biosciences Inc (TYRA) on Vested. To buy Tyra Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TYRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tyra Biosciences Inc (TYRA) via the Vested app. You can start investing in Tyra Biosciences Inc (TYRA) with a minimum investment of $1.
You can invest in shares of Tyra Biosciences Inc (TYRA) via Vested in three simple steps:
The 52-week high price of Tyra Biosciences Inc (TYRA) is $29.6. The 52-week low price of Tyra Biosciences Inc (TYRA) is $11.24.
The price-to-earnings (P/E) ratio of Tyra Biosciences Inc (TYRA) is
The price-to-book (P/B) ratio of Tyra Biosciences Inc (TYRA) is 2.13
The dividend yield of Tyra Biosciences Inc (TYRA) is 0.00%
The market capitalization of Tyra Biosciences Inc (TYRA) is $770.18M
The stock symbol (or ticker) of Tyra Biosciences Inc is TYRA